Pharma-Bio Serv (PBSV) releases full-year 2025 results in January 29 press note

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. reported that it has released its financial results for the year ended October 31, 2025. The company announced these full-year results through a press release dated January 29, 2026, which is attached to this report as Exhibit 99.1.

The filing emphasizes that the press release and related financial information are being furnished rather than filed, meaning they are not automatically incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001304161false00013041612026-01-292026-01-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 29, 2026

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-50956		20-0653570
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

PO Box 1049 Dorado, Puerto Rico		00646
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (787) 278-2709 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class Trading Symbol(s) Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 29, 2026, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the year ended October 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 29, 2026.
104		Cover page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHARMA-BIO SERV, INC.
Date: January 29, 2026	By:	/s/ Pedro J. Lasanta
		Pedro J. Lasanta
		Chief Financial Officer, Vice President Finance and Administration and Secretary

3

FAQ

What did Pharma-Bio Serv (PBSV) disclose in this 8-K filing?

Pharma-Bio Serv disclosed that it released its financial results for the year ended October 31, 2025. The results are contained in a press release dated January 29, 2026, which is attached as Exhibit 99.1 to the current report.

Which period do Pharma-Bio Serv’s newly released results cover?

The announced results cover Pharma-Bio Serv’s fiscal year ended October 31, 2025. These full-year results are summarized in a press release furnished with the filing as Exhibit 99.1, dated January 29, 2026, rather than detailed directly in the report.

How did Pharma-Bio Serv (PBSV) communicate its 2025 annual results?

Pharma-Bio Serv communicated its 2025 annual results through a press release dated January 29, 2026. That press release is furnished as Exhibit 99.1 to the 8-K, providing investors with the company’s operational and financial performance for the fiscal year.

Is the Pharma-Bio Serv 2025 results press release considered filed with the SEC?

The press release is furnished, not filed, under Item 2.02 of the 8-K. This means it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced by the company.

Where can investors find Pharma-Bio Serv’s detailed 2025 financial results?

Investors can find detailed 2025 financial results in the press release attached as Exhibit 99.1. The 8-K notes that this press release, dated January 29, 2026, contains the company’s results for the year ended October 31, 2025.

What exhibits are included with Pharma-Bio Serv’s January 29, 2026 8-K?

The filing includes Exhibit 99.1, a press release dated January 29, 2026, presenting results for the year ended October 31, 2025. It also includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.